Ergomed plc

About Ergomed plc

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Our background in co-development means we understand what it takes to deliver drugs to the market quickly and responsibly.

https://www.ergomedplc.com

ERGO.L United Kingdom

1,292USD8 (+0.62%)

• At close Fri Feb 03 2023

LSE exchange

Sector: Healthcare

Industry: Biotechnology

Location United Kingdom, Guildford

Grade: ADA

732,095,411 USD
MARKET CAP
67.604
PE
0.977
BETA (5y)
19.200
EPS

Profits

for 5 years
545%
for 3 years
177%
for 2 years
19%
for last year
14%
for this year
-4%
Ergomed plc
© 2023 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.